Indivior (NASDAQ:INDV) Reaches New 12-Month High – Still a Buy?

Indivior PLC (NASDAQ:INDV)’s stock price hit a new 52-week high on Wednesday . The stock traded as high as $25.00 and last traded at $24.48, with a volume of 198644 shares changing hands. The stock had previously closed at $24.46.

Analyst Ratings Changes

INDV has been the topic of several analyst reports. Wall Street Zen raised shares of Indivior from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 21st. Craig Hallum lifted their price target on shares of Indivior from $27.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright initiated coverage on shares of Indivior in a report on Wednesday, August 6th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Indivior in a report on Tuesday, July 22nd. They set a “buy” rating and a $20.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $22.00.

Indivior Price Performance

The firm’s fifty day moving average price is $18.63 and its 200 day moving average price is $13.42.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, July 31st. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.26 by $0.25. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. The firm had revenue of $302.00 million for the quarter, compared to the consensus estimate of $239.43 million. Indivior has set its FY 2025 guidance at EPS. As a group, research analysts expect that Indivior PLC will post 1.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Indivior

Several large investors have recently bought and sold shares of INDV. Deerfield Management Company L.P. Series C increased its position in Indivior by 74.4% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company’s stock worth $110,418,000 after purchasing an additional 3,790,518 shares during the last quarter. Geode Capital Management LLC increased its position in Indivior by 1,122.6% during the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after acquiring an additional 1,447,939 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Rubric Capital Management LP increased its position in Indivior by 31.6% during the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after acquiring an additional 1,117,140 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after acquiring an additional 958,132 shares during the last quarter. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.